Efficacy and tolerability of Citrus/Cydonia comp.® solution for injection in patients with grass pollen seasonal allergic rhinitis:

Randomised, double-blind, placebocontrolled comparative clinical trial with three parallel treatment groups

Published: 27-01-2014 Last updated: 19-03-2025

1. Clinically relevant reduction of symptom severity by use of Citrus/Cydonia comp. subcutaneous injections 2. To examine the use of rescue medication in the three groups, 3.safety of treatment

Ethical reviewApproved WMOStatusRecruitment stoppedHealth condition typeAllergic conditionsStudy typeInterventional

Summary

ID

NL-OMON40456

Source

ToetsingOnline

Brief title

The CiSAR Study

Condition

Allergic conditions

Synonym

grass pollen allergy, hay fever

1 - Efficacy and tolerability of Citrus/Cydonia comp.® solution for injection in pa ... 13-05-2025

Research involving

Human

Sponsors and support

Primary sponsor: Hogeschool Leiden

Source(s) of monetary or material Support: Weleda AG

Intervention

Keyword: grass pollen allergy, herbal medicinal product, immuno therapy, placebo controlled clinical trial

Outcome measures

Primary outcome

Days with symptom control defined by: a)A Total Symptom Score of * 8 (while exposed to a mean pollen count of 20-50) or * 12 (while exposed to a mean pollen count of > 50) and b)No use of rescue medication in the verum group compared to the placebo group in the last two weeks of treatment

Secondary outcome

- 1. Total use of rescue medication throughout the whole treatment period.
- 2. Number of drop outs between verum and placebo group. 4. Safety: Adverse events

Study description

Background summary

Considering the high prevalence of allergic rhinitis and the fact that a significant number of sufferers with severe symptoms are resistant to treatment with usual pharmacotherapy (antihistamines and topical nasal corticosteroids) (Wilson et al., 2005), there still is a space and need for the development of new treatment concepts. Citrus/Cydonia comp. is an anthroposophic medicine, which contains lemon juice (Citrus limon, succus) and a aqueous extract from quince (Cydonia oblonga, fructus rec., 1:2.1). For over eighty years now, Citrus/Cydonia comp. is being prescribed as a subcutaneous injection or as a nasal spray for patients who suffer from seasonal allergic rhinitis. In several

European countries, Citrus/Cydonia comp. is commercially available under the trade name *Gencydo®* for the prophylaxis and treatment of allergic diseases, specifically those affecting the respiratory tract such as hay fever. A survey on clinical experiences, carried out among a group of 39 general practitioners in the Netherlands, indicates that the subcutaneous treatment with Citrus/Cydonia comp. ampoules is profoundly effective (Bruin et al., 2001). Firstly, a permanent effect from the treatment with Citrus/Cydonia comp. tends to be experienced, which indicates that the patients in question are claiming to lastingly suffer less from hay fever or even that they are free from complaints. Secondly, the effect is occurring within a period of two weeks, up to three months, after the actual treatment. Thirdly, the effect is optimal after a treatment of several years. In a therapeutic causality report, positive effects with Citrus/Cydonia comp. were observed in a group of 13 patients suffering from grass pollen mediated hay fever (Baars et al., 2005). In most patients, Citrus/Cydonia comp. injections were given before the onset of and during the grass pollen season and symptom severity did not increase during the pollen season. Furthermore, 69% of the patients reported an improvement of symptoms. In addition, a prospective, observational study on the effect of Citrus/Cydonia comp. nasal spray on hay fever symptoms reported positive results without side effects in 140 patients (Rother and Oexle, 2008). Recently, the immunological pathways underlying the positive effects of Citrus/Cydonia comp. in patients with seasonal allergic rhinitis were studied (Baars and Savelkoul, 2008). Therefore, peripheral blood mononuclear cells (PMBCs) were isolated from a healthy and an allergic donor and the effect of Citrus/Cydonia comp. on differentiation capacity and Th1 (e.g. IFN-*) and Th2 (e.g. IL-5) cells was examined. Citrus/Cydonia comp. showed a selective effect on the differentiation of T-cells by producing relatively more IL-10 than IL-12. Furthermore, it also had an effect on the induction of regulatory (IL-10 producing) T-cell subsets. It was therefore concluded that Citrus/Cydonia comp. can potentially restore the disturbed immune state of allergic rhinitis patients by modulation of the Th1-Th2 balance. This immunotherapeutic potency and the positive results from the observed clinical cases, form the rational to further evaluate the effects of Citrus/Cydonia comp. in seasonal allergic rhinitis. Recently it was demonstrated in a comparative study of two different routes of administration of Citrus/Cydonia comp. 1%, that subcutaneous injections resulted in larger clinical effects on nasal and non-nasal allergic rhinitis symptom severity in patients suffering seasonal allergic rhinitis compared to the nasal administration. The subcutaneous route was also more effective in the differentiation and induction of (regulatory) T-cells and the balancing of the Th1 and Th2 pathways (Baars et al., 2009). Based on the considerations laid down above, Citrus/Cydonia comp. may be an effective and safe treatment for seasonal allergic rhinitis.

Study objective

- 1. Clinically relevant reduction of symptom severity by use of Citrus/Cydonia comp. subcutaneous injections 2. To examine the use of rescue medication in the
 - 3 Efficacy and tolerability of Citrus/Cydonia comp.® solution for injection in pa ... 13-05-2025

Study design

Randomised, double-blind, placebo-controlled comparative clinical trial with three parallel treatment groups

Intervention

Due to weather conditions the pollen level can be (too) low. In order to get the optimal conditions for the study the period of the total time for wash out and/or treatment will be extended for all subjects.

2-3 weeks wash-out period, depending on the pollen season

6-8 weeks intervention period depending on the pollen season

After a 2-week (3 weeks in case of extended treatment) run in period the patients will be randomised to a 6 weeks treatment period (8 weeks in case of extended treatment). Either: 6 weeks (8 weeks in case of extended treatment) of subcutaneous injection of Citrus/Cydonia comp. ® 1% solution twice a week or: 6 weeks (8 weeks in case of extended treatment) of subcutaneous injection of 0.9% saline solution (placebo) twice a week or 6 weeks (8 weeks in case of extended treatment) of subcutaneous injection of Citrus/Cydonia comp. ® 1-5% solution twice a week

Study burden and risks

In the 2 weeks (3 weeks in case of extended treatment) before onset of the study, participants cannot use regular hay fever medication which will result in an increase of hay fever symptoms. (For treatment with cromoglycates it is a period of 4 weeks). They can use rescue medication (antihistaminicum) according protocol guidelines during the 8 (11 weeks in case of extended treatment) weeks of the study. All participating patients will receive 2 times a week a subcutaneous injection during 6 weeks (8 weeks in case of extended treatment). There are no known side effects of the subcutaneous administration of Citrus/ Cydonia comp. or placebo injection other than local and small pain symptoms that last for only a short amount of time. All participating patients will complete an online questionnaire once a day (2 minutes) during 8 weeks (11 weeks in case of extended treatment). Next to this there is an intake visit, where medical history is discussed and a short physical examination is (bloodpressure, heart/ lungs/ ENT) is accomplished (total visit: about 1 hour), and there will be one telephone call by the investigator (5 minutes). In case of extended treatment there will be 1 extra thelephone call at week 5 (5 minutes)

Contacts

Public

Hogeschool Leiden

Zernikedreef 11 Leiden 2333 CK L NL

Scientific

Hogeschool Leiden

Zernikedreef 11 Leiden 2333 CK L NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Patients: *Written informed consent *Age * 18 and < 60 years. *Seasonal AR: -Duration of respective complaints at least 2 years -Suffering from the following nasal symptoms: sneezing, itching nose, nasal obstruction and watery nasal discharge -Severity score of at least two of the four nasal symptoms * 2; ranging from $0 \le 10^{10}$ not present to $0 \le 10^{10}$ nor present to $0 \le 10^{10}$

Exclusion criteria

Patients: *Chronic autoimmune disease such as Diabetes Mellitus type 1, Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis or Crohn*s disease *Known hypersensitivity to one of the constituents of Citrus/Cydonia comp.® *Participation in a further clinical trial at the same time or within 4 weeks prior to enrolment into this study *Previous use of medicinal products containing Citrus and/or Cydonia *Pregnancy or lactation *Severe internal or systemic disease (e.g. cardiac, hepatic, renal diseases) *A known history of drug, alcohol and/or medication dependence or addiction *Immunotherapy in the last two years . * Use of cromoglycates *Other allergies (non seasonal allergies)

Study design

Design

Study phase: 3

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Double blinded (masking used)

Control: Placebo

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 01-02-2014

Enrollment: 126

Type: Actual

Medical products/devices used

Product type: Medicine

Brand name: Citrus/ Cydonia comp.

Generic name: Citrus/ Cydonia comp.

Ethics review

Approved WMO

Date: 27-01-2014

Application type: First submission

Review commission: METC Brabant (Tilburg)

Approved WMO

Date: 13-06-2016

Application type: First submission

Review commission: METC Brabant (Tilburg)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 27660

Source: Nationaal Trial Register

Title:

In other registers

Register ID

EudraCT EUCTR2013-004897-92-NL

CCMO NL47143.028.13 OMON NL-OMON27660